U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07932444) titled 'Melatonin in Stroke' on May 13.
Brief Summary: Acute ischemic stroke (AIS) is a leading cause of mortality and disability worldwide, placing a substantial burden on healthcare systems and society.1 Despite intensive advancements in the stroke care, incomplete neurological recovery after stroke is quite common, with many survivors experiencing persistent motor, cognitive, or sensory deficits.2 These long-term impairments significantly affect the quality of life and highlight the need for additional neurorestorative therapies.3,4 The pathophysiology of ischemic stroke involves a complex cascade of events including excitotoxicity, oxid...